NURS 607 / N607 EXAM 2 STUDY GUIDE
(MODULES 5-9) | 2026 UDATED WITH COMPLETE
SOLUTIONS - MCNEESE STATE UNIVERSITY.
148 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 607 / N607 EXAM 2 STUDY GUIDE (MODULES 5-9) | 2026 UDATED WITH COMPLETE SOLUTIONS -
MCNEESE STATE UNIVERSITY.. It contains 148 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 148 Questions
Foundations - Application - NURS 607 / N607 2 Study Guide Modules 5-9 2026 Udated WITH Complete
Solutions - Mcneese State University Advanced Nursing Modules 5 9 Advanced Pharmacology
Pathophysiology Health Assessment AND Evidence-based Clinical Decision-making Graduate Msn/dnp-level
Nursing NURS 607
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Advanced Health 1-25 Prescribed, Teaching, Laboratory, Effect, Medication
Assessment AND Diagnostic
Reasoning
Pharmacological 26-50 Prescribed, Receiving, Finding, Understanding, Indicates
Management AND
Prescribing Considerations
Pathophysiology OF Acute 51-75 Prescribed, Medication, Therapy, Indicates, Receiving
AND Chronic Conditions
Clinical Decision-making 76-100 Receiving, Finding, Prescribed, Instruction, Infusion
AND Differential Diagnosis
Patient Education AND 101-125 Finding, Laboratory, Prescribed, Receiving, Reflects
Health Promotion
CARE Coordination AND 126-148 Prescribed, Finding, Intervention, Receiving, Preparing
Interprofessional
Collaboration
TOTAL 148 All questions include answers and detailed rationales
,Section A - Advanced Health Assessment AND Diagnostic
Reasoning
Q1.
A patient with atrial fibrillation is prescribed apixaban. Which laboratory parameter best
reflects the drug's therapeutic anticoagulant effect in routine monitoring?
A. INR B. aPTT
C. Anti-factor Xa activity D. Bleeding time
Correct: C - Anti-factor Xa activity
Rationale:Apixaban is a direct factor Xa inhibitor, and its anticoagulant effect is best
assessed by anti-factor Xa activity when monitoring is needed. INR and aPTT are not reliable
for direct oral anticoagulants. Bleeding time does not reflect factor Xa inhibition.
Why the other answers are wrong:
A. INR reflects the extrinsic pathway and is used for warfarin, not apixaban.
B. aPTT reflects the intrinsic pathway and is insensitive to direct factor Xa inhibitors.
D. Bleeding time assesses platelet function, not factor Xa inhibition.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52
Q2.
A patient with heart failure has an ejection fraction of 30% and persistent symptoms
despite optimized beta-blocker and ACE inhibitor therapy. Which additional agent is most
strongly supported by current guidelines?
A. Verapamil B. Sacubitril/valsartan
C. Furosemide as monotherapy D. Amlodipine
Correct: B - Sacubitril/valsartan
Rationale:Sacubitril/valsartan is a guideline-directed therapy for HFrEF and improves
outcomes when added to optimized beta-blocker and ACE inhibitor/ARB therapy. Verapamil
and amlodipine are not first-line for HFrEF and may worsen outcomes. Furosemide treats
congestion but does not improve mortality.
Why the other answers are wrong:
A. Verapamil is a non-dihydropyridine calcium channel blocker that can worsen HFrEF.
C. Loop diuretics relieve congestion but do not improve survival in HFrEF.
D. Amlodipine is not a guideline-directed therapy for HFrEF mortality benefit.
Reference: 2022 AHA/ACC/HFSA Heart Failure Guideline; Lehne, 12th Ed., Ch. 46
Page 3
, Section A - Advanced Health Assessment AND Diagnostic Reasoning
Q3.
Which finding on a comprehensive health assessment is most consistent with a diagnosis
of metabolic syndrome?
A. BMI 23 kg/m², fasting glucose 92 mg/dL, B. Waist circumference 40 inches,
BP 118/74 mmHg triglycerides 180 mg/dL, HDL 38 mg/dL
C. LDL 100 mg/dL, total cholesterol 180 D. Hemoglobin 11.2 g/dL, ferritin 12 ng/mL,
mg/dL, BMI 24 kg/m² TIBC elevated
Correct: B - Waist circumference 40 inches, triglycerides 180 mg/dL, HDL 38 mg/dL
Rationale:Metabolic syndrome requires at least three of five criteria: elevated waist
circumference, triglycerides 150 mg/dL, HDL <40 mg/dL (men), elevated BP, or elevated
fasting glucose. Option B meets three criteria. The other options do not meet the diagnostic
threshold.
Why the other answers are wrong:
A. These values are within normal limits and do not meet criteria.
C. These lipid and BMI values are not diagnostic for metabolic syndrome.
D. These findings suggest iron-deficiency anemia, not metabolic syndrome.
Reference: NHLBI/AHA Metabolic Syndrome Criteria; Jarvis, Physical Examination & Health
Assessment, 9th Ed.
Q4.
A patient on warfarin is started on fluconazole for a fungal infection. Which monitoring
action is most appropriate to prevent an adverse outcome?
A. Increase warfarin dose empirically B. Monitor INR closely and anticipate a dose
reduction
C. Discontinue warfarin and start aspirin D. No change needed; fluconazole does not
interact
Correct: B - Monitor INR closely and anticipate a dose reduction
Rationale:Fluconazole inhibits CYP2C9, which metabolizes warfarin, increasing INR and
bleeding risk. Close INR monitoring with anticipated warfarin dose reduction is required.
Empiric dose increases or substituting aspirin are unsafe.
Why the other answers are wrong:
A. Increasing warfarin would worsen bleeding risk due to CYP2C9 inhibition.
C. Switching to aspirin does not address the interaction and increases GI bleeding risk.
D. Fluconazole is a significant CYP2C9 inhibitor and does interact with warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52
Page 4
(MODULES 5-9) | 2026 UDATED WITH COMPLETE
SOLUTIONS - MCNEESE STATE UNIVERSITY.
148 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 607 / N607 EXAM 2 STUDY GUIDE (MODULES 5-9) | 2026 UDATED WITH COMPLETE SOLUTIONS -
MCNEESE STATE UNIVERSITY.. It contains 148 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 148 Questions
Foundations - Application - NURS 607 / N607 2 Study Guide Modules 5-9 2026 Udated WITH Complete
Solutions - Mcneese State University Advanced Nursing Modules 5 9 Advanced Pharmacology
Pathophysiology Health Assessment AND Evidence-based Clinical Decision-making Graduate Msn/dnp-level
Nursing NURS 607
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Advanced Health 1-25 Prescribed, Teaching, Laboratory, Effect, Medication
Assessment AND Diagnostic
Reasoning
Pharmacological 26-50 Prescribed, Receiving, Finding, Understanding, Indicates
Management AND
Prescribing Considerations
Pathophysiology OF Acute 51-75 Prescribed, Medication, Therapy, Indicates, Receiving
AND Chronic Conditions
Clinical Decision-making 76-100 Receiving, Finding, Prescribed, Instruction, Infusion
AND Differential Diagnosis
Patient Education AND 101-125 Finding, Laboratory, Prescribed, Receiving, Reflects
Health Promotion
CARE Coordination AND 126-148 Prescribed, Finding, Intervention, Receiving, Preparing
Interprofessional
Collaboration
TOTAL 148 All questions include answers and detailed rationales
,Section A - Advanced Health Assessment AND Diagnostic
Reasoning
Q1.
A patient with atrial fibrillation is prescribed apixaban. Which laboratory parameter best
reflects the drug's therapeutic anticoagulant effect in routine monitoring?
A. INR B. aPTT
C. Anti-factor Xa activity D. Bleeding time
Correct: C - Anti-factor Xa activity
Rationale:Apixaban is a direct factor Xa inhibitor, and its anticoagulant effect is best
assessed by anti-factor Xa activity when monitoring is needed. INR and aPTT are not reliable
for direct oral anticoagulants. Bleeding time does not reflect factor Xa inhibition.
Why the other answers are wrong:
A. INR reflects the extrinsic pathway and is used for warfarin, not apixaban.
B. aPTT reflects the intrinsic pathway and is insensitive to direct factor Xa inhibitors.
D. Bleeding time assesses platelet function, not factor Xa inhibition.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52
Q2.
A patient with heart failure has an ejection fraction of 30% and persistent symptoms
despite optimized beta-blocker and ACE inhibitor therapy. Which additional agent is most
strongly supported by current guidelines?
A. Verapamil B. Sacubitril/valsartan
C. Furosemide as monotherapy D. Amlodipine
Correct: B - Sacubitril/valsartan
Rationale:Sacubitril/valsartan is a guideline-directed therapy for HFrEF and improves
outcomes when added to optimized beta-blocker and ACE inhibitor/ARB therapy. Verapamil
and amlodipine are not first-line for HFrEF and may worsen outcomes. Furosemide treats
congestion but does not improve mortality.
Why the other answers are wrong:
A. Verapamil is a non-dihydropyridine calcium channel blocker that can worsen HFrEF.
C. Loop diuretics relieve congestion but do not improve survival in HFrEF.
D. Amlodipine is not a guideline-directed therapy for HFrEF mortality benefit.
Reference: 2022 AHA/ACC/HFSA Heart Failure Guideline; Lehne, 12th Ed., Ch. 46
Page 3
, Section A - Advanced Health Assessment AND Diagnostic Reasoning
Q3.
Which finding on a comprehensive health assessment is most consistent with a diagnosis
of metabolic syndrome?
A. BMI 23 kg/m², fasting glucose 92 mg/dL, B. Waist circumference 40 inches,
BP 118/74 mmHg triglycerides 180 mg/dL, HDL 38 mg/dL
C. LDL 100 mg/dL, total cholesterol 180 D. Hemoglobin 11.2 g/dL, ferritin 12 ng/mL,
mg/dL, BMI 24 kg/m² TIBC elevated
Correct: B - Waist circumference 40 inches, triglycerides 180 mg/dL, HDL 38 mg/dL
Rationale:Metabolic syndrome requires at least three of five criteria: elevated waist
circumference, triglycerides 150 mg/dL, HDL <40 mg/dL (men), elevated BP, or elevated
fasting glucose. Option B meets three criteria. The other options do not meet the diagnostic
threshold.
Why the other answers are wrong:
A. These values are within normal limits and do not meet criteria.
C. These lipid and BMI values are not diagnostic for metabolic syndrome.
D. These findings suggest iron-deficiency anemia, not metabolic syndrome.
Reference: NHLBI/AHA Metabolic Syndrome Criteria; Jarvis, Physical Examination & Health
Assessment, 9th Ed.
Q4.
A patient on warfarin is started on fluconazole for a fungal infection. Which monitoring
action is most appropriate to prevent an adverse outcome?
A. Increase warfarin dose empirically B. Monitor INR closely and anticipate a dose
reduction
C. Discontinue warfarin and start aspirin D. No change needed; fluconazole does not
interact
Correct: B - Monitor INR closely and anticipate a dose reduction
Rationale:Fluconazole inhibits CYP2C9, which metabolizes warfarin, increasing INR and
bleeding risk. Close INR monitoring with anticipated warfarin dose reduction is required.
Empiric dose increases or substituting aspirin are unsafe.
Why the other answers are wrong:
A. Increasing warfarin would worsen bleeding risk due to CYP2C9 inhibition.
C. Switching to aspirin does not address the interaction and increases GI bleeding risk.
D. Fluconazole is a significant CYP2C9 inhibitor and does interact with warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52
Page 4
